S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NASDAQ:CVET

Covetrus - CVET Stock Forecast, Price & News

$20.83
+0.02 (+0.10%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$20.80
$20.85
50-Day Range
$20.50
$20.85
52-Week Range
$13.39
$24.29
Volume
431,593 shs
Average Volume
949,615 shs
Market Capitalization
$2.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.40

Covetrus MarketRank™ Forecast

Analyst Rating
Hold
1.83 Rating Score
Upside/​Downside
2.7% Upside
$21.40 Price Target
Short Interest
Healthy
4.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of Covetrus in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.04 M Sold Last Quarter
Proj. Earnings Growth
21.95%
From $0.82 to $1.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Computer And Technology Sector

383rd out of 663 stocks

Drug Stores & Proprietary Stores Industry

3rd out of 6 stocks

CVET stock logo

About Covetrus (NASDAQ:CVET) Stock

Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CVET shares. Morgan Stanley increased their price target on Covetrus from $19.00 to $21.00 and gave the company an "equal weight" rating in a research report on Monday, May 23rd. The Goldman Sachs Group reduced their price target on Covetrus from $18.00 to $16.00 and set a "sell" rating on the stock in a research report on Thursday, May 19th. William Blair lowered Covetrus from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 25th. Raymond James lowered Covetrus from an "outperform" rating to a "market perform" rating in a research report on Monday, May 23rd. Finally, Barclays lowered Covetrus from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $26.00 to $21.00 in a research report on Thursday, May 26th. One analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. According to data from MarketBeat, Covetrus currently has a consensus rating of "Hold" and a consensus target price of $21.40.

Covetrus Stock Up 0.1 %

Shares of NASDAQ:CVET traded up $0.02 during midday trading on Monday, hitting $20.83. 431,593 shares of the company's stock were exchanged, compared to its average volume of 1,328,228. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.88 and a quick ratio of 1.08. Covetrus has a twelve month low of $13.39 and a twelve month high of $24.29. The company has a market cap of $2.92 billion, a PE ratio of -208.30 and a beta of 1.68. The firm's fifty day simple moving average is $20.74 and its 200-day simple moving average is $18.37.

Insiders Place Their Bets

In other Covetrus news, CEO Benjamin Wolin sold 5,292 shares of Covetrus stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $20.80, for a total transaction of $110,073.60. Following the transaction, the chief executive officer now owns 199,780 shares of the company's stock, valued at $4,155,424. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Covetrus news, CEO Benjamin Wolin sold 5,292 shares of Covetrus stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $20.80, for a total transaction of $110,073.60. Following the transaction, the chief executive officer now owns 199,780 shares of the company's stock, valued at $4,155,424. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward Mcnamara sold 34,525 shares of Covetrus stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $20.52, for a total value of $708,453.00. Following the transaction, the director now directly owns 31,807 shares in the company, valued at approximately $652,679.64. The disclosure for this sale can be found here. Insiders have sold a total of 50,403 shares of company stock valued at $1,037,392 over the last quarter. Company insiders own 0.60% of the company's stock.

Receive CVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

CVET Stock News Headlines

Covetrus Announces Retirement of Matthew Foulston
Form PRER14A COVETRUS, INC. - StreetInsider.com
Covetrus (CVET) Q2 Earnings Match Estimates
See More Headlines
Receive CVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

CVET Company Calendar

Last Earnings
2/28/2021
Today
8/16/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Drug stores & proprietary stores
Sub-Industry
N/A
Current Symbol
NASDAQ:CVET
Fax
N/A
Employees
5,710
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.40
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+2.7%
Consensus Rating
Hold
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$-54,000,000.00
Pretax Margin
-0.56%

Debt

Sales & Book Value

Annual Sales
$4.58 billion
Cash Flow
$2.19 per share
Book Value
$10.97 per share

Miscellaneous

Free Float
139,131,000
Market Cap
$2.92 billion
Optionable
Not Optionable
Beta
1.68

Key Executives

  • Mr. Benjamin Wolin (Age 46)
    Pres, CEO & Director
    Comp: $1.02M
  • Mr. Matthew J. Foulston (Age 57)
    Exec. VP & Global CFO
    Comp: $624.66k
  • Ms. Georgina Wraight (Age 47)
    Exec. VP & Pres of Global Technology Solutions
    Comp: $563.4k
  • Mr. Dustin k. Finer (Age 52)
    Chief Admin. Officer
    Comp: $552.67k
  • Mr. Matthew Malenfant (Age 60)
    Chief Commercial Officer
    Comp: $533.62k
  • Ms. Rebecca Kidd (Age 53)
    Head of Operations & Operational Excellence
  • Mr. Andrew B. Coxhead (Age 53)
    VP, Corp. Controller & Chief Accounting Officer
  • Mr. Nicholas Michael Jansen
    VP of Investor Relations
  • Ms. Ditte Marstrand Wulf (Age 51)
    Global Chief HR Officer
  • Mr. Russell Cooke (Age 56)
    Sr. VP & Operational CFO













CVET Stock - Frequently Asked Questions

Should I buy or sell Covetrus stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating and 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CVET shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVET, but not buy additional shares or sell existing shares.
View CVET analyst ratings
or view top-rated stocks.

What is Covetrus' stock price forecast for 2022?

6 analysts have issued 12 month target prices for Covetrus' shares. Their CVET share price forecasts range from $16.00 to $27.00. On average, they predict the company's stock price to reach $21.40 in the next twelve months. This suggests a possible upside of 2.7% from the stock's current price.
View analysts price targets for CVET
or view top-rated stocks among Wall Street analysts.

How have CVET shares performed in 2022?

Covetrus' stock was trading at $19.97 at the start of the year. Since then, CVET stock has increased by 4.3% and is now trading at $20.83.
View the best growth stocks for 2022 here
.

When is Covetrus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CVET earnings forecast
.

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) announced its quarterly earnings data on Sunday, February, 28th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.05. The firm had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.06 billion. Covetrus had a negative net margin of 0.28% and a positive trailing twelve-month return on equity of 6.83%. The business's revenue for the quarter was up 11.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.18 earnings per share.

What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus Chief Executive Officer Benjamin Wolin on Glassdoor.com. Benjamin Wolin has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (2.77%), Northern Trust Corp (0.95%), Alpine Associates Management Inc. (0.90%), Frontier Capital Management Co. LLC (0.80%), Jennison Associates LLC (0.67%) and Citadel Advisors LLC (0.59%). Insiders that own company stock include Anthony C Jr Providenti, Benjamin Shaw, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Erin Powers Brennan, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis and Timothy Ludlow.
View institutional ownership trends
.

How do I buy shares of Covetrus?

Shares of CVET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $20.83.

How much money does Covetrus make?

Covetrus (NASDAQ:CVET) has a market capitalization of $2.92 billion and generates $4.58 billion in revenue each year. The company earns $-54,000,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Covetrus have?

The company employs 5,710 workers across the globe.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The official website for the company is www.henryscheinvet.com. The company can be reached via phone at (888) 280-2221 or via email at nicholas.jansen@covetrus.com.

This page (NASDAQ:CVET) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.